RapidAI RAPID Platform
Clinical software platform for neurovascular and vascular care that analyzes medical imaging, supports case notification and team coordination, and provides workflow and operational analytics to hospitals.
Why Abandoned
RapidAI continues to market and support the RAPID Platform on its official website. The company announced FDA clearance for Rapid SDH in January 2024 and an expanded partnership with the World Stroke Organization in October 2024, indicating ongoing product development and commercial activity.
🩺 Health Signals
No checks have been run on this tool yet.
📅 Timeline
iSchemaView founded
DAWN and DEFUSE 3 expand the role of RAPID imaging
$25 million financing announced
Company rebrands as RapidAI
RapidAI acquires EndoVantage
Rapid SDH receives FDA clearance
🪦 Other dead Healthcare tools
Kheiron Mia
🟡Acquired / MergedMia is Kheiron Medical Technologies’ artificial intelligence platform for breast-screening mammography. It supports radiologists by analyzing mammograms and identifying cases that may warrant further review.
MaxQ AI ACCIPIO
🟠Possibly DeadACCIPIO was MaxQ AI's clinical AI platform for analyzing non-contrast head CT scans and prioritizing suspected intracranial hemorrhage cases for radiologist review. It was a triage aid, not a standalone diagnosis system.
Arterys Cardio AI
🟡Acquired / MergedCloud-based cardiac MRI analysis software that used machine learning to assist clinicians with image segmentation, ventricular measurements, and cardiac function assessment. Tempus acquired Arterys in 2022.
Zebra Medical Vision Imaging Analytics
🟡Acquired / MergedAI-based medical imaging analytics developed by Zebra Medical Vision to help identify findings in radiology scans. Nanox acquired Zebra in 2021 and incorporated its software into the Nanox.AI portfolio.
❓ Frequently Asked Questions
What is the RapidAI RAPID Platform?
The RAPID Platform is a hospital clinical-software suite that applies algorithms to medical images and connects results with case notification, care-team communication, workflow tools and analytics, particularly for stroke and other neurovascular conditions.
How does RapidAI support stroke care?
RapidAI analyzes CT and MR imaging for findings relevant to stroke workflows, sends case information and alerts to authorized clinicians, and supports communication intended to help teams coordinate evaluation, transfer and treatment.
Is the RapidAI RAPID Platform FDA cleared?
Individual RapidAI modules have received FDA clearances, but clearance is product- and indication-specific. Healthcare organizations should verify the applicable labeling and regulatory status for each module and jurisdiction rather than treating the entire platform as one clearance.
Who founded RapidAI?
The business was founded as iSchemaView by Stanford-affiliated imaging specialists Dr. Roland Bammer and Dr. Greg Albers. It adopted the RapidAI name in 2020.
Is RapidAI still active?
Yes. RapidAI continues to operate its website and announce product and partnership developments. Its January 2024 Rapid SDH clearance and October 2024 World Stroke Organization partnership announcement provide recent evidence of ongoing activity.